The Antibody Drug Conjugate, Belantamab-Mafodotin, in the Treatment of Multiple Myeloma: A Comprehensive Review
Adrian Alfonso Almodovar Diaz, Samhar Samer Alouch, Yogesh Chawla, Wilson I Gonsalves · 2024
Read The Antibody Drug Conjugate, Belantamab-Mafodotin, in the Treatment of Multiple Myeloma: A Comprehensive Review by Adrian Alfonso Almodovar Diaz, Samhar Samer Alouch, Yogesh Chawla, Wilson I Gonsalves (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11631777.txt.
Description
Adrian Alfonso Almodovar Diaz, Samhar Samer Alouch, Yogesh Chawla, and Wilson Gonsalves review a targeted drug for multiple myeloma, a blood cancer that usually returns after treatment. Their 2024 review focuses on belantamab-mafodotin, the first antibody-drug conjugate aimed at a protein found on malignant plasma cells. Such conjugates pair an antibody with a poison payload, delivered straight to the cancer.
The drug's antibody homes to the target protein, and its payload breaks the cell's internal scaffolding, triggering death. A series of trials, called the DREAMM studies, tested the drug in many settings. The review gathers preclinical and clinical evidence for patients whose disease resisted standard therapies.
Catalog record
| CREATOR | Adrian Alfonso Almodovar Diaz, Samhar Samer Alouch, Yogesh Chawla, Wilson I Gonsalves |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |